Emerging psychoactive substance use among regular ecstasy users in Australia.
Drug and alcohol dependence July 1, 2012 Raimondo Bruno, Allison J Matthews, Matthew Dunn et al. 58 citations
More than a quarter (28%) of regular ecstasy users in Australia had used an emerging psychoactive substance (EPS) in the past six months, most often a stimulant like mephedrone (17%) rather than a psychedelic like 5-MeO-DMT (13%). Users of stimulant EPS resembled mainstream ecstasy users in demographics and risk behaviors, while psychedelic EPS users were a distinct subgroup who started ecstasy earlier, used more multiple substances (cannabis, inhalants, GHB, ketamine), and experienced more legal, psychological, and social problems. The demographic similarity of stimulant EPS consumers and positive responses to these drugs, combined with declining ecstasy purity, suggest stimulant EPS may expand further into ecstasy markets and pose greater public health risks.